UPDATE: GLP-1 Patent Landscape & Market Disruption Following our analysis yesterday on GLP-1 receptor agonist patent expirations and market consolidation, emerging energy sector volatility—driven by fragmented oil supply chains reported by Oil & Gas 360—presents secondary economic context: pharmaceutical manufacturing costs (particularly for cold-chain biologics) remain tethered to energy price fluctuations, which historically impact margins for GLP-1 producers during scale-up phases. This supply-side pressure compounds the existing patent cliff dynamics we documented, potentially accelerating timeline pressures for branded GLP-1 manufacturers to establish manufacturing redundancy before generic competition intensifies post-patent expiration.